PBPK modeling approaches to assess risks associated with bioequivalence in drug development On-Demand Webinar

In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed: Opportunities and challenges in conducting virtual bioequivalenceIVIVE-PBPK in biopharmaceuticsAn quantitative risk assessment approach for virtual bioequivalenceRole of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence

Using Authoring Templates to Write the Right Way On-Demand Webinar

Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to be eCTD compliant the first time comes with its unique challenges. To address these challenges, Certara Synchrogenix paired its technical experts with its regulatory writers...

Similarities and differences between SNDS and other claim databases On-Demand Webinar

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than 99% of the French population and about 10% of Europe....

Stakeholder perspectives: current and potential benefits On-Demand Webinar

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than 99% of the French population and about 10% of Europe....

De-risk your program with evidence-based secondary pharmacology insights On-Demand Webinar

Safety issues account for about a quarter of the attrition in drug projects and can arise from either the primary or secondary pharmacology. To address secondary pharmacology, researchers typically screen their small molecule compounds against a broad panel of off-target...

Your First Choice in Complex Biologics Drug Development Video

The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide therapeutics, immuno-oncology therapies, vaccines, antibody-drug conjugates, bispecific antibodies, and cell and gene therapies. These drugs can be challenging to develop for multiple reasons. Certara provides...

Certara Acquires UK-based Insight Medical Writing Press Release

Expands global reach and deepens regulatory expertise PRINCETON, NJ.— June 10, 2021– Certara, Inc., the global leader in biosimulation, today announced the acquisition of Insight Medical Writing, based in Oxford in the United Kingdom.  Financial terms of the transaction were...